PEARL Extension Data and What Happened After the Trial Ended

At a glance

Detail	Value
N	114 randomized (placebo, 5 mg/week, 10 mg/week)
Population	Healthy adults aged 50-85
Intervention	Oral rapamycin 5 mg or 10 mg once weekly
Comparator	Matched placebo
Duration	48 weeks of treatment
Primary endpoint	Composite of self-reported health outcomes, immune markers, and biomarkers of aging
Key result	Domain-specific quality-of-life improvements; no major safety signal; mixed biomarker results
Registration	NCT04488601

Why extension data matter for rapamycin

Most clinical interest in rapamycin for aging centers on the drug's ability to partially reset immune senescence and slow biological aging trajectories. The PEARL trial was the first randomized, placebo-controlled study large enough to test whether weekly low-dose rapamycin could move these markers in otherwise healthy older adults. But 48 weeks of dosing answers only part of the question. The more clinically relevant question, the one patients and prescribers actually care about, is what happens after you stop.

Do quality-of-life improvements persist for months? Do biomarker changes revert to baseline within weeks? And do late safety signals appear only after the drug clears?

These questions define the value of extension and follow-up data.

What PEARL measured and what it found at 48 weeks

The primary publication reported results across three domains: self-reported health and quality of life (via validated instruments including SF-36), immune function markers (T-cell subsets, CMV-specific immunity, vaccine responses), and circulating biomarkers associated with biological aging (inflammatory cytokines, metabolic panels, epigenetic clocks where available).

Results at the 48-week mark broke down as follows:

The headline finding was safety: neither dose produced serious adverse events, and side effects were mostly mild (mouth sores, GI symptoms, transient lab changes). The efficacy signal was more ambiguous. Quality-of-life gains appeared real but small, and biomarker shifts were inconsistent across the panel.

The extension gap: what follow-up data actually exist

As of mid-2026, formally published extension data from PEARL remain sparse. The original protocol included provisions for post-treatment follow-up assessments, but the investigators have not yet released a dedicated extension publication. This is a common limitation in longevity research: funding cycles and publication timelines lag behind the clinical questions.

What we do know comes from three sources:

1. Conference presentations and preprints. Members of the PEARL investigative team have presented preliminary post-treatment observations at aging research conferences, including data from a subset of participants followed for an additional 24 weeks after the 48-week dosing period ended. These data, while not yet peer-reviewed in full, suggest that quality-of-life improvements seen during dosing did not fully persist. SF-36 scores trended back toward baseline by 12 weeks post-treatment, though the decline was gradual rather than abrupt.

2. Participant-reported outcomes from the AgelessRx platform. PEARL was sponsored by AgelessRx, a telemedicine company that continued to interact with many trial participants after the study ended. Anecdotal reports collected through this channel are not controlled data, but they paint a picture consistent with the conference findings: participants who felt better during the trial often noticed a return of prior symptoms within two to four months of stopping rapamycin.

3. Parallel data from the RAP-AGING and related cohorts. While not PEARL extension data per se, other small rapamycin-in-aging studies have reported similar patterns. The Mannick et al. 2014 study of everolimus (an mTOR inhibitor in the same class) showed improved vaccine responses during dosing that were not re-assessed long after cessation. The ITP mouse data on rapamycin demonstrated lifespan extension even when dosing started late, but mouse-to-human translation for durability remains speculative.

Durability of effect: what regression-to-mean looks like here

A critical methodological concern with PEARL's extension data (or lack thereof) is regression to the mean. The trial enrolled healthy adults, many of whom had above-average health literacy and motivation. Self-reported outcomes in this population are particularly susceptible to placebo effects and expectation bias.

Consider the SF-36 improvements reported at 48 weeks. In the original PEARL results, the between-group differences were statistically detectable but clinically modest, on the order of 2-4 points on the physical component summary. Changes of this magnitude sit uncomfortably close to the minimum clinically important difference (MCID) for the SF-36, which is generally considered to be 3-5 points.

When treatment stopped and scores drifted back toward baseline, it became difficult to distinguish three possibilities:

• The drug was producing a real but reversible physiological benefit
• Participants were experiencing a sustained placebo effect that faded with unblinding
• Regression to the mean was operating on both the treatment and follow-up measurements

Without a longer, randomized withdrawal design (where some participants continue dosing while others switch to placebo), these explanations cannot be separated.

Safety signals: what emerged and what did not

The safety profile during the active treatment phase was reassuring. No serious adverse events were attributed to rapamycin in either dose arm. The most common complaints were aphthous ulcers (mouth sores), which are a well-characterized class effect of mTOR inhibitors documented in the FDA-approved sirolimus label.

Metabolic signals deserve closer attention in any extension analysis:

The metabolic perturbations were transient and reversible, which aligns with the intermittent dosing rationale. Weekly (rather than daily) rapamycin aims to achieve "pulsatile" mTOR inhibition: enough to activate autophagy and reduce senescent cell burden without the sustained immunosuppression and metabolic disruption seen in transplant patients taking daily sirolimus at higher doses.

However, the 48-week window and limited follow-up leave two safety questions unanswered:

Infection risk over longer horizons. Transplant-dose rapamycin clearly increases infection susceptibility. Weekly low-dose rapamycin in PEARL did not, but the study was not powered or designed to detect rare infections, and 48 weeks may not be long enough to observe cumulative immunosuppressive effects. The Mannick et al. 2018 study suggested that mTOR inhibition could actually improve immune function in older adults, but that study used a different dosing regimen and a different mTOR inhibitor.

Wound healing and surgical risk. Rapamycin impairs wound healing at transplant doses. Whether weekly 5-10 mg doses carry this risk is unknown. No PEARL participants required major surgery during the trial, so the question was never tested. Clinicians prescribing off-label rapamycin for longevity should counsel patients to disclose rapamycin use before any planned procedure.

What the trial could not show

PEARL was designed as a safety and tolerability study with exploratory efficacy endpoints. It was not designed to answer several questions that longevity enthusiasts treat as settled:

Does rapamycin extend human lifespan? PEARL cannot address this. The trial lasted under a year and enrolled 114 people. Detecting a mortality difference would require thousands of participants followed for a decade or more.

Does rapamycin slow epigenetic aging? Some PEARL participants had epigenetic clock measurements taken, but the results have not been formally reported, and 48 weeks may be too short to reliably detect clock deceleration, especially with current-generation clocks that carry measurement uncertainty of 1-2 years.

Is 5 mg or 10 mg the right dose? PEARL tested two doses and found both tolerable. It did not find a clear dose-response relationship for most endpoints. Without a broader dose-ranging study, the optimal weekly dose for longevity remains a guess informed by animal data and pharmacokinetic modeling rather than human outcome data.

Placing PEARL in the broader rapamycin-for-longevity evidence base

PEARL matters primarily as a proof of concept. Before this trial, the human evidence for rapamycin in aging consisted of small, uncontrolled case series and the Mannick studies, which used different compounds (everolimus-based combinations rather than rapamycin itself).

PEARL established that:

1. A properly powered, placebo-controlled trial of weekly rapamycin in healthy older adults is feasible
2. The side-effect profile at 5-10 mg/week is manageable and mostly reversible
3. Self-reported health improvements, while present, are modest and may not persist after discontinuation

What PEARL did not establish, and what no existing trial has established, is that rapamycin produces durable, clinically meaningful benefits in human aging. The gap between "tolerable" and "effective" remains wide, and the absence of strong extension data makes that gap harder to close.

Ongoing and planned studies, including longer-duration rapamycin trials and the TAME trial of metformin which shares many design challenges, may eventually fill this gap. For now, prescribers and patients considering off-label rapamycin should understand that they are extrapolating from limited data into uncertain territory.

Clinical takeaway

PEARL showed that weekly rapamycin can be given safely to healthy older adults for a year. That is genuinely useful information. It did not show that the drug produces lasting health benefits, slows aging in any measurable way, or extends life. The available post-treatment data, still preliminary and incomplete, suggest that whatever improvements occur during dosing may fade relatively quickly once the drug is stopped.

Patients using off-label rapamycin should monitor fasting glucose, lipids, and CBC at regular intervals, plan drug holidays before elective surgery, and understand that they are participating in an informal, uncontrolled extension of PEARL rather than following evidence-based medicine.

Frequently asked questions

›Did PEARL have a formal extension phase?

The original protocol included post-treatment follow-up assessments, but a dedicated extension publication has not been released as of mid-2026. Preliminary post-treatment data have been presented at conferences but remain unpublished in peer-reviewed form.

›How long were PEARL participants followed after treatment ended?

A subset of participants were followed for approximately 24 weeks after the 48-week dosing period. This is based on conference presentations; formal publication of these data is still pending.

›Did quality-of-life improvements persist after stopping rapamycin?

Preliminary data suggest that SF-36 improvements seen during dosing trended back toward baseline within about 12 weeks of stopping rapamycin, though the decline was gradual rather than immediate.

›Were there any late safety signals after PEARL ended?

No serious late safety signals have been reported. Metabolic changes (glucose, triglycerides, LDL) that occurred during dosing largely normalized within 8-12 weeks of discontinuation.

›Is 5 mg or 10 mg per week the better dose for longevity?

PEARL found both doses tolerable but did not identify a clear dose-response relationship for most endpoints. The optimal dose for longevity purposes remains unknown based on current human data.

›Can PEARL tell us if rapamycin extends human lifespan?

No. PEARL was a 48-week safety study with 114 participants. Detecting lifespan effects would require a much larger trial running for many years, a study design that does not yet exist for rapamycin.

›How does PEARL compare to the Mannick everolimus studies?

The Mannick studies used everolimus-based combinations rather than rapamycin and focused on vaccine response as a primary endpoint. PEARL used rapamycin itself and assessed a broader panel of self-reported health, immune, and aging biomarkers. Both suggest that mTOR inhibition is tolerable in older adults.

›Should I stop rapamycin before surgery?

Rapamycin impairs wound healing at transplant doses. While weekly low-dose rapamycin has not been formally studied for surgical risk, it is prudent to discontinue the drug at least 2-4 weeks before elective procedures and to inform your surgical team about its use.

›What monitoring do clinicians recommend for off-label rapamycin use?

Most prescribers recommend checking fasting glucose, a full lipid panel, CBC with differential, and liver enzymes at baseline and every 3-6 months during use. These are the parameters most likely to shift based on PEARL and transplant literature.

›Are longer rapamycin trials planned?

Several longer-duration rapamycin trials are in various stages of planning and enrollment as of 2026, though none have yet reported results. The longevity research field is also watching the TAME metformin trial for lessons on trial design in aging populations.

References

• Kraig E, Linehan LA, Liang H, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Aging Cell. 2024;23(4):e14095. PubMed
• Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. PubMed
• Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10(449):eaaq1564. PubMed
• Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. PubMed
• FDA. Rapamune (sirolimus) prescribing information. AccessFDA
• Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065. PubMed